Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Ultragenyx Pharmaceutical Inc shares valued at $393,853 were sold by Horn Howard on Oct 10 ’24. At $52.76 per share, Horn Howard sold 7,465 shares. The insider’s holdings dropped to 92,301 shares worth approximately $4.25 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, KAKKIS EMIL D sold 20,000 shares, netting a total of over 1,117,000 in proceeds. Following the sale of shares at $55.85 each, the insider now holds 2,223,985 shares.
Before that, Huizenga Theodore Alan had sold 91 shares from its account. In a trade valued at $5,113, the SVP, Chief Accounting Officer traded Ultragenyx Pharmaceutical Inc shares for $56.19 each. Upon closing the transaction, the insider’s holdings decreased to 91 shares, worth approximately $1.91 million.
As published in a research note from Goldman on June 06, 2024, Ultragenyx Pharmaceutical Inc [RARE] has been rated up from a Neutral to a Buy and the price target has been revised to $67 from $56. Analysts at RBC Capital Mkts started covering the stock with ‘”an Outperform”‘ outlook in a report released in late April. As of December 08, 2023, Wells Fargo has initiated its “an Overweight” rating for RARE.
Analyzing RARE Stock Performance
During the last five days, there has been a drop of approximately -3.40%. Over the course of the year, Ultragenyx Pharmaceutical Inc shares have dropped approximately -3.76%. Shares of the company reached a 52-week high of $60.37 on 09/16/24 and a 52-week low of $37.02 on 06/18/24. A 50-day SMA is recorded $53.37, while a 200-day SMA reached $48.12. Nevertheless, trading volume fell to 0.53 million shares from 0.7 million shares the previous day.
Support And Resistance Levels for Ultragenyx Pharmaceutical Inc (RARE)
According to the 24-hour chart, there is a support level at 45.57, which, if violated, would cause prices to drop to 45.12. In the upper region, resistance lies at 46.81. The next price resistance is at 47.59. RSI (Relative Strength Index) is 34.61 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -2.40, which suggests the price will decrease in the coming days. Percent R is at 71.43%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.
